Sermo docs favor McCain's healthcare plan

Share this article:

Forty-four percent of Sermo physicians polled found Senator McCain's healthcare plan to be “beneficial to the country,” compared with 30% that said Senator Obama's is beneficial.

Additionally, 51% said Obama's plan is not beneficial for the country, versus 31% who said McCain's plan is not beneficial.

Sermo's polling was conducted following a Q&A with both candidates – McCain and Obama were asked to respond to five questions each. The questions posed to both candidates were proposed and voted on by Sermo physicians. 

After reviewing the answers from each camp, 30% of the polled physicians said the candidates' answers would change their vote from the candidate they'd previously supported. Twenty-three percent of those who read Obama's answers said they were influenced toward McCain, while 10% of the respondents said McCain's answers had swayed them toward Obama.

The polling closed on Friday, October 31, according to a Sermo spokesperson. Sermo is the largest physician-only online community, with approximately 90,000 US physician members. A ballpark number of physicians that participated in the poll weren't immediately available, although the spokesperson said it was “in the thousands.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...